Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00504504 · ClinicalTrials.gov registry record · Phase 2
Rituximab and ABVD for Hodgkin's Patients
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 85
- Enrollment target
NCT00504504: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00504504 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 85 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00504504, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 85 participants
- Enrollment target
Study Summary
Primary Objective: \- To determine the feasibility, toxicity, and efficacy of Rituximab with standard dose ABVD combination chemotherapy. ABVD combination chemotherapy consists of Adriamycin, Bleomycin, Vinblastine and DTIC.
Interventions
- DRUG Rituximab
- DRUG Vinblastine
- DRUG Bleomycin
- DRUG Adriamycin
- DRUG Dacarbazine (DTIC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2001-03 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00504504
The ClinicalTrials.gov registry entry for NCT00504504 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Rituximab is the first listed.
NCT00504504 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00504504 about?
NCT00504504 is a clinical study titled "Rituximab and ABVD for Hodgkin's Patients". Primary Objective: \- To determine the feasibility, toxicity, and efficacy of Rituximab with standard dose ABVD combination chemotherapy. ABVD combination chemotherapy consists of Adriamycin, Bleomycin, Vinblastine and DTIC.
What is the current status of trial NCT00504504?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2001-03. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00504504?
The interventions under investigation include: Rituximab (DRUG), Vinblastine (DRUG), Bleomycin (DRUG), Adriamycin (DRUG), Dacarbazine (DTIC) (DRUG).
Who is sponsoring clinical trial NCT00504504?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.